Kevin Charron, MD
Sports Medicine · Carrollton, GANPI 1699898437
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,118 of the $33,008 with a category attached, or 85.2%. Arthrex accounts for 88.8% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $16,958 and has fallen 94.0% since, to $1,021 in 2025. Among sports medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $343.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$29K
- United Orthopedics LLC$2K
- Amgen$577
- ERMI LLC$92
- AbbVie$83
- Pacira Therapeutics, Inc.$81
- plus $542 from 20 others
What the payments were for
- Speaking & faculty fees$28,11885%
- Travel & lodging$1,6755%
- Food & beverage$1,4985%
- Education$1,7175%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 20 | $29,303 |
| United Orthopedics LLC | 3 | $2,330 |
| Amgen | 37 | $577 |
| ERMI LLC | 2 | $92 |
| AbbVie | 3 | $83 |
| Pacira Therapeutics, Inc. | 5 | $81 |
| Johnson & Johnson | 2 | $58 |
| Illuminoss Medical, Inc. | 1 | $54 |
| Vertos Medical, Inc. | 1 | $45 |
| Zimmer Biomet | 1 | $45 |
| Ferring Pharmaceuticals Inc. | 3 | $38 |
| Orthogenrx Inc. | 2 | $35 |
| Davol Inc. | 1 | $30 |
| Smith+Nephew | 1 | $30 |
| Zyla Life Sciences, Inc. | 2 | $28 |
| Endo USA, Inc. | 1 | $25 |
| Bioventus LLC | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Orthofix Medical, Inc. | 2 | $18 |
| Heron Therapeutics, Inc. | 1 | $15 |
| Integra Lifesciences Corporation | 1 | $14 |
| Vericel Corporation | 1 | $13 |
| Heraeus Medical, LLC. | 1 | $13 |
| Polarityte, Inc. | 1 | $11 |
| Kerecis Limited | 1 | $11 |
How this compares
$33,008 in reported general payments places this provider in the 90th percentile of 168 sports medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 268 | $6,008 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 273 | $2,525 |
| Diclofenac Sodium | 186 | $2,009 |
| Methylprednisolone | 175 | $1,105 |
| Tramadol Hcl | 130 | $549 |
| Ondansetron Hcl | 83 | $523 |
| Meloxicam | 193 | $473 |
| Gabapentin | 21 | $248 |
| Diclofenac Sodium ErDiclofenac Sodium | 11 | $224 |
| Cyclobenzaprine Hcl | 16 | $140 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $131 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 13 | $108 |
| Naproxen | 11 | $37 |
| Lorazepam | 11 | $8 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Carrollton
- Robert O'ConnellCarrollton$69K
- Shomari RuffinCarrollton$9K
- John XerogeanesAtlanta$4M
- Joseph BurnsAlpharetta$376K
- Sameh LabibBrookhaven$280K
- Spero KarasAtlanta$137K
- Xavier DuraldeAtlanta$77K
- Thomas MyersAtlanta$72K
- Elan GolanSnellville$57K
- Taylor PolanderJesup$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.